BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

341 related articles for article (PubMed ID: 1568247)

  • 1. Somatic mutations in the neurofibromatosis 1 gene in human tumors.
    Li Y; Bollag G; Clark R; Stevens J; Conroy L; Fults D; Ward K; Friedman E; Samowitz W; Robertson M
    Cell; 1992 Apr; 69(2):275-81. PubMed ID: 1568247
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Analysis of the GAP-related domain of the neurofibromatosis type 1 (NF1) gene in childhood brain tumors.
    Scheurlen WG; Senf L
    Int J Cancer; 1995 Aug; 64(4):234-8. PubMed ID: 7657385
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The GAP-related domain of the neurofibromatosis type 1 gene product interacts with ras p21.
    Martin GA; Viskochil D; Bollag G; McCabe PC; Crosier WJ; Haubruck H; Conroy L; Clark R; O'Connell P; Cawthon RM
    Cell; 1990 Nov; 63(4):843-9. PubMed ID: 2121370
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identification and characterization of the neurofibromatosis type 1 protein product.
    DeClue JE; Cohen BD; Lowy DR
    Proc Natl Acad Sci U S A; 1991 Nov; 88(22):9914-8. PubMed ID: 1946460
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mutational analysis of N-RAS and GAP-related domain of the neurofibromatosis type 1 gene in chronic myelogenous leukemia.
    Garicochea B; Giorgi R; Odone VF; Dorlhiac-Llacer PE; Bendit I
    Leuk Res; 1998 Nov; 22(11):1003-7. PubMed ID: 9783802
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Selective disactivation of neurofibromin GAP activity in neurofibromatosis type 1.
    Klose A; Ahmadian MR; Schuelke M; Scheffzek K; Hoffmeyer S; Gewies A; Schmitz F; Kaufmann D; Peters H; Wittinghofer A; Nürnberg P
    Hum Mol Genet; 1998 Aug; 7(8):1261-8. PubMed ID: 9668168
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mutational and functional analysis of the neurofibromatosis type 1 (NF1) gene.
    Upadhyaya M; Osborn MJ; Maynard J; Kim MR; Tamanoi F; Cooper DN
    Hum Genet; 1997 Jan; 99(1):88-92. PubMed ID: 9003501
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Suppression of oncogenic Ras by mutant neurofibromatosis type 1 genes with single amino acid substitutions.
    Nakafuku M; Nagamine M; Ohtoshi A; Tanaka K; Toh-e A; Kaziro Y
    Proc Natl Acad Sci U S A; 1993 Jul; 90(14):6706-10. PubMed ID: 8341688
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Interaction between a Domain of the Negative Regulator of the Ras-ERK Pathway, SPRED1 Protein, and the GTPase-activating Protein-related Domain of Neurofibromin Is Implicated in Legius Syndrome and Neurofibromatosis Type 1.
    Hirata Y; Brems H; Suzuki M; Kanamori M; Okada M; Morita R; Llano-Rivas I; Ose T; Messiaen L; Legius E; Yoshimura A
    J Biol Chem; 2016 Feb; 291(7):3124-34. PubMed ID: 26635368
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Molecular genetics of neurofibromatosis type 1].
    Suzuki H; Takahashi K; Shibahara S
    Nihon Rinsho; 1993 Sep; 51(9):2457-61. PubMed ID: 8411728
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A conserved alternative splice in the von Recklinghausen neurofibromatosis (NF1) gene produces two neurofibromin isoforms, both of which have GTPase-activating protein activity.
    Andersen LB; Ballester R; Marchuk DA; Chang E; Gutmann DH; Saulino AM; Camonis J; Wigler M; Collins FS
    Mol Cell Biol; 1993 Jan; 13(1):487-95. PubMed ID: 8417346
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Neurofibromatosis type 1 (NF1) gene: implication in neuroectodermal differentiation and genesis of brain tumors.
    Nishi T; Saya H
    Cancer Metastasis Rev; 1991 Dec; 10(4):301-10. PubMed ID: 1786631
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Loss of neurofibromin is associated with activation of RAS/MAPK and PI3-K/AKT signaling in a neurofibromatosis 1 astrocytoma.
    Lau N; Feldkamp MM; Roncari L; Loehr AH; Shannon P; Gutmann DH; Guha A
    J Neuropathol Exp Neurol; 2000 Sep; 59(9):759-67. PubMed ID: 11005256
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A RASopathy gene commonly mutated in cancer: the neurofibromatosis type 1 tumour suppressor.
    Ratner N; Miller SJ
    Nat Rev Cancer; 2015 May; 15(5):290-301. PubMed ID: 25877329
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Assessment of the potential pathogenicity of missense mutations identified in the GTPase-activating protein (GAP)-related domain of the neurofibromatosis type-1 (NF1) gene.
    Thomas L; Richards M; Mort M; Dunlop E; Cooper DN; Upadhyaya M
    Hum Mutat; 2012 Dec; 33(12):1687-96. PubMed ID: 22807134
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Neurofibromatosis type 1 peripheral nerve tumors: aberrant activation of the Ras pathway.
    Feldkamp MM; Angelov L; Guha A
    Surg Neurol; 1999 Feb; 51(2):211-8. PubMed ID: 10029430
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The GTPase-activating NF1 fragment of 91 amino acids reverses v-Ha-Ras-induced malignant phenotype.
    Nur-E-Kamal MS; Varga M; Maruta H
    J Biol Chem; 1993 Oct; 268(30):22331-7. PubMed ID: 8226742
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Differential expression of two types of the neurofibromatosis type 1 (NF1) gene transcripts related to neuronal differentiation.
    Nishi T; Lee PS; Oka K; Levin VA; Tanase S; Morino Y; Saya H
    Oncogene; 1991 Sep; 6(9):1555-9. PubMed ID: 1923522
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Two NF1 mutations: frameshift in the GAP-related domain, and loss of two codons toward the 3' end of the gene.
    Abernathy CR; Colman SD; Kousseff BG; Wallace MR
    Hum Mutat; 1994; 3(4):347-52. PubMed ID: 8081387
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The neurofibromatosis gene in human pituitary adenomas.
    Pei L; Melmed S
    Endocr Pathol; 1994 Dec; 5(4):229-232. PubMed ID: 32138455
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.